1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,151 | 0,171 | 23.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.12. | SINOMAB BIO-B (03681): VOLUNTARY ANNOUNCEMENT IND APPLICATION FOR SM17 ACCEPTED BY NMPA CDE | - | HKEx | ||
| 14.10. | SINOMAB BIO-B (03681): VOLUNTARY ANNOUNCEMENT FIRST COHORT OF HEALTHY SUBJECTS DOSED WITH SUBCUTANEOUS FORMULATION OF SM17 IN A BRIDGING STUDY IN CHINA | - | HKEx | ||
| 08.10. | SINOMAB BIO-B (03681): CHANGE OF COMPANY SECRETARY | 1 | HKEx | ||
| 26.09. | SINOMAB BIO-B (03681): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS AND REPLY FORM | 2 | HKEx | ||
| SINOMAB BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| 26.09. | SINOMAB BIO-B (03681): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM | - | HKEx | ||
| 26.09. | SINOMAB BIO-B (03681): INTERIM REPORT 2025 | - | HKEx | ||
| 29.08. | SINOMAB BIO-B (03681): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2025 | - | HKEx | ||
| 29.08. | SINOMAB BIO-B (03681): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 29.08. | SINOMAB BIO-B (03681): COMPLETION OF SUBSCRIPTIONS OF NEW SHARES UNDER GENERAL MANDATE | - | HKEx | ||
| 18.08. | SINOMAB BIO-B (03681): DATE OF BOARD MEETING | 1 | HKEx | ||
| 15.08. | SINOMAB BIO-B (03681): NEXT DAY DISCLOSURE RETURN | 3 | HKEx | ||
| 15.08. | SINOMAB BIO-B (03681): COMPLETION OF CERTAIN SUBSCRIPTIONS OF NEW SHARES UNDER GENERAL MANDATE | 1 | HKEx | ||
| 12.08. | SINOMAB BIO-B (03681): VOLUNTARY ANNOUNCEMENT COMPREHENSIVE STRATEGIC COOPERATION AGREEMENT | 1 | HKEx | ||
| 24.07. | SINOMAB BIO-B (03681): GRANT OF SHARE OPTIONS | 1 | HKEx | ||
| 22.07. | SINOMAB BIO-B (03681): SUBSCRIPTIONS OF NEW SHARES UNDER GENERAL MANDATE | 3 | HKEx | ||
| 14.07. | SINOMAB BIO-B (03681): INSIDE INFORMATION UPDATE ON THE BLA FOR SM03 (SUCIRASLIMAB) IN THE TREATMENT OF RHEUMATOID ARTHRITIS | - | HKEx | ||
| 30.06. | SINOMAB BIO-B (03681): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE ADOPTED BY THE BOARD ON 30 JUNE, 2025 | 1 | HKEx | ||
| 30.06. | SINOMAB BIO-B (03681): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 30.06. | SINOMAB BIO-B (03681): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 30 JUNE 2025, APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTORS, CHANGE IN ... | - | HKEx | ||
| 09.04. | SinoMab BioScience Limited Breakthrough Phase 1b POC Results for SM17 in Atopic Dermatitis | 470 | JCN Newswire | - Potentially a First-and Best-in-Class Product- Combining Deep Pruritus Relief, Effective Skin Clearance, and a Well-tolerated Safety ProfileHONG KONG, Apr 9, 2025 - (ACN Newswire) - SinoMab BioScience... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 275,73 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 | BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| ARCELLX | 65,51 | 0,00 % | Arcellx a new overweight at Wells Fargo on promise of multiple myeloma CAR-T asset | ||
| NUVALENT | 104,83 | 0,00 % | Royalty-Pharma-Deal stützt Nuvalent: UBS bekräftigt Kaufempfehlung | ||
| STRUCTURE THERAPEUTICS | 71,33 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| IMMUNOME | 21,730 | 0,00 % | Immunome: Guggenheim bestätigt Kaufempfehlung nach 400-Millionen-Dollar-Finanzierung | ||
| IMMUNOVANT | 26,760 | 0,00 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 29,310 | 0,00 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 83,53 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,370 | 0,00 % | Cathie Wood's ARK sells Tesla stock, buys Coinbase and Recursion Pharmaceuticals | ||
| COGENT BIOSCIENCES | 40,165 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 82,13 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| CG ONCOLOGY | 40,050 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates | Initiated rolling Biologics License Application (BLA) submission to U.S. FDA for cretostimogene monotherapy in high-risk (HR) BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)Demonstrated... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 21,745 | 0,00 % | Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | BOULDER, Colo., Dec. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical... ► Artikel lesen | |
| QIAGEN | 38,985 | -0,35 % | QIAGEN N.V.: QIAGEN gibt Details zum Abschluss des synthetischen Aktienrückkaufs über bis zu rund $500 Mio. bekannt | Kapitalrückzahlung durch synthetischen Aktienrückkauf kombiniert schnelle, unmittelbare Kapitalrückzahlung an Aktionärinnen und Aktionäre mit einer Aktienzusammenlegung zur Steigerung des Gewinns... ► Artikel lesen | |
| DYNE THERAPEUTICS | 20,410 | 0,00 % | Dyne Therapeutics appoints Vikram Karnani to board of directors |
SINOMAB BIOSCIENCE LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +22,98 % bei einem Aktienkurs von 0,198 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SINOMAB BIOSCIENCE LTD finden Sie auf Wallstreet Online.